touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer.
The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy.’ (Abstract number CT564) was presented at AACR 2022, 8-13 April, 2022
Questions
- In what groups of patients with bladder cancer have treatment benefits been demonstrated with the immune checkpoint inhibitor, pembrolizumab? (0:21)
- What is the rationale for combining pembrolizumab and chemoradiotherapy in patients who choose bladder preservation? (1:16)
- Please can you describe the eligibility criteria for patients enrolled in the KEYNOTE-992 study including stratification subgroups? (3:12)
- What treatments will patients receive, including permitted radiotherapy and radiosensitizing chemotherapy regimens? (4:22)
- How will efficacy be assessed in the study and what are the key endpoints? (6:01)
Disclosures: Neal Shore discloses consulting for Abbvie, Amgen, Asieris, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Sema4, Specialty Networks, Sesen Bio, Telix, Tempus, Tolmar, Urogen and Vaxiion.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AACR annual meeting 2022.
